# A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

> **NCT05261126** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 381 (actual)

## Conditions studied

- Hypercholesterolemia
- Familial Hypercholesterolemia

## Interventions

- **DRUG:** Enclitide Chloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05261126
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-10
- **Primary completion:** 2022-11-28
- **Final completion:** 2022-11-28
- **Target enrollment:** 381 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05261126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05261126, "A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05261126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*